Tobias Nagler

Tobias Nagler, MD is Professor of Hematology and Oncology at Charité University Medical Center Berlin and Head of the Stem Cell Transplantation Unit. He is a leading European expert in the immunotherapeutic treatment of acute lymphoblastic leukemia, particularly in the setting of relapsed and refractory disease. Dr. Nagler has been deeply involved in European clinical trials evaluating blinatumomab and inotuzumab ozogamicin in B-ALL, contributing importantly to the understanding of optimal sequencing of novel agents, the management of toxicities, and the role of allogeneic stem cell transplantation following novel immunotherapy-induced remissions. He has led and contributed to studies examining the integration of CAR-T cell therapy (tisagenlecleucel and others) with allogeneic SCT in the curative treatment algorithm for pediatric and young adult ALL, providing insights into whether bridging to transplant after CAR-T remission improves outcomes. His research on post-transplant MRD surveillance and the use of donor lymphocyte infusions to prevent relapse after allogeneic SCT has been widely applied in European hematology centers. Dr. Nagler is an active member of the European Society for Blood and Marrow Transplantation (EBMT) and has contributed to multiple EBMT registry studies characterizing outcomes of ALL treatment across Europe.